cccc-20240331

000166257912-312023Q1FALSEhttp://fasb.org/us-gaap/2023#CollaborativeArrangementMemberhttp://fasb.org/us-gaap/2023#CollaborativeArrangementMemberSubsequent events

On October 30, 2023, the Board of Directors approved the Company's decision to not advance CFT8634 beyond the Phase 1 dose escalation portion of the Phase 1/2 clinical trial. Costs associated with the decision to suspend the program are not expected to be material

xbrli:sharesiso4217:USDiso4217:USDxbrli:sharescccc:performanceObligationcccc:targetxbrli:purecccc:proteincccc:position00016625792024-01-012024-03-3100016625792024-04-3000016625792024-03-3100016625792023-12-3100016625792023-01-012023-03-310001662579us-gaap:CommonStockMember2023-12-310001662579us-gaap:AdditionalPaidInCapitalMember2023-12-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001662579us-gaap:RetainedEarningsMember2023-12-310001662579us-gaap:CommonStockMembercccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMembercccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579cccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579us-gaap:CommonStockMembercccc:AtTheMarketMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMembercccc:AtTheMarketMember2024-01-012024-03-310001662579cccc:AtTheMarketMember2024-01-012024-03-310001662579us-gaap:CommonStockMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001662579us-gaap:RetainedEarningsMember2024-01-012024-03-310001662579us-gaap:CommonStockMember2024-03-310001662579us-gaap:AdditionalPaidInCapitalMember2024-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001662579us-gaap:RetainedEarningsMember2024-03-310001662579us-gaap:CommonStockMember2022-12-310001662579us-gaap:AdditionalPaidInCapitalMember2022-12-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001662579us-gaap:RetainedEarningsMember2022-12-3100016625792022-12-310001662579us-gaap:CommonStockMember2023-01-012023-03-310001662579us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001662579us-gaap:RetainedEarningsMember2023-01-012023-03-310001662579us-gaap:CommonStockMember2023-03-310001662579us-gaap:AdditionalPaidInCapitalMember2023-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001662579us-gaap:RetainedEarningsMember2023-03-3100016625792023-03-310001662579cccc:StockPurchaseAgreementMember2023-01-012023-03-310001662579cccc:AtTheMarketMember2023-01-012023-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMember2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001662579us-gaap:CorporateDebtSecuritiesMember2024-03-310001662579us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001662579us-gaap:USTreasurySecuritiesMember2024-03-310001662579us-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:USTreasurySecuritiesMember2023-12-310001662579cccc:LaboratoryEquipmentMember2024-03-310001662579cccc:LaboratoryEquipmentMember2023-12-310001662579us-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-03-310001662579us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-12-310001662579us-gaap:FurnitureAndFixturesMember2024-03-310001662579us-gaap:FurnitureAndFixturesMember2023-12-310001662579us-gaap:OfficeEquipmentMember2024-03-310001662579us-gaap:OfficeEquipmentMember2023-12-310001662579us-gaap:ComputerEquipmentMember2024-03-310001662579us-gaap:ComputerEquipmentMember2023-12-310001662579us-gaap:SubsequentEventMembercccc:MKDGAgreementMember2024-05-012024-05-020001662579cccc:DiscoveryRegulatoryAndCommercialMilestonesMembercccc:MKDGAgreementMember2024-03-310001662579srt:MinimumMembercccc:MKDGAgreementMember2024-03-312024-03-310001662579cccc:MKDGAgreementMember2024-03-310001662579cccc:MKDGAgreementMember2024-03-310001662579cccc:MerckAgreementMember2024-01-012024-01-310001662579cccc:ResearchAndDevelopmentMilestonesMembercccc:MerckAgreementMember2023-12-110001662579cccc:MerckAgreementMember2023-12-110001662579srt:MinimumMembercccc:MerckAgreementMember2024-03-312024-03-310001662579cccc:MerckAgreementMember2024-03-310001662579cccc:BettaAgreementMember2023-05-292023-05-290001662579cccc:ResearchAndDevelopmentMilestonesMembercccc:BettaAgreementMember2023-05-290001662579cccc:DrugApplicationApprovalMembercccc:BettaAgreementMember2023-05-290001662579cccc:BettaAgreementMember2023-05-290001662579srt:MinimumMember2023-05-292023-05-290001662579cccc:BettaAgreementMember2024-03-310001662579cccc:BettaAgreementMember2024-03-312024-03-310001662579cccc:BettaAgreementMember2024-01-012024-03-310001662579us-gaap:ForeignCountryMember2024-01-012024-03-310001662579cccc:RestatedRocheAgreementMember2018-12-012018-12-310001662579cccc:RestatedRocheAgreementMember2020-11-300001662579cccc:RestatedRocheAgreementMember2023-12-310001662579cccc:RestatedRocheAgreementMembercccc:LeadSeriesIdentificationAchievementMember2020-11-012020-11-300001662579cccc:RestatedRocheAgreementMember2020-11-012020-11-300001662579srt:MaximumMembercccc:RestatedRocheAgreementMembercccc:ResearchDevelopmentAndCommercialMilestonePaymentsMember2020-11-300001662579srt:MaximumMembercccc:RestatedRocheAgreementMembercccc:OneTimeSalesBasedPaymentsMember2020-11-300001662579cccc:RestatedRocheAgreementMembersrt:MinimumMember2020-11-012020-11-3000016625792018-12-310001662579cccc:RestatedRocheAgreementMember2018-12-310001662579cccc:ResearchAndDevelopmentTargetsMember2024-03-310001662579cccc:OptionRightsMember2024-03-310001662579srt:MaximumMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579srt:MaximumMembercccc:ResearchAndDevelopmentMilestonesMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579srt:MaximumMembercccc:OneTimeSalesBasedPaymentsMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:BiogenResearchAndLicenseAgreementMember2024-03-310001662579cccc:BiogenResearchAndLicenseAgreementMembercccc:ResearchAndDevelopmentServicesMember2024-01-012024-03-310001662579us-gaap:SubsequentEventMembercccc:BiogenResearchAndLicenseAgreementMember2024-04-012024-04-300001662579cccc:CalicoLicenseAgreementMember2017-03-012017-03-310001662579cccc:CalicoLicenseAgreementMember2021-08-012021-08-310001662579cccc:CalicoLicenseAgreementMember2017-03-012020-06-300001662579srt:MaximumMembercccc:CalicoLicenseAgreementMembercccc:PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember2017-03-012017-03-310001662579srt:MaximumMembercccc:CalicoLicenseAgreementMembercccc:OneTimeSalesBasedPaymentsMember2017-03-012017-03-310001662579cccc:MKDGAgreementMember2024-01-012024-03-310001662579cccc:MKDGAgreementMember2023-01-012023-03-310001662579cccc:MerckAgreementMember2024-01-012024-03-310001662579cccc:MerckAgreementMember2023-01-012023-03-310001662579cccc:RocheAgreementMember2024-01-012024-03-310001662579cccc:RocheAgreementMember2023-01-012023-03-310001662579cccc:BiogenAgreementMember2024-01-012024-03-310001662579cccc:BiogenAgreementMember2023-01-012023-03-310001662579cccc:CalicoAgreementMember2024-01-012024-03-310001662579cccc:CalicoAgreementMember2023-01-012023-03-310001662579cccc:RocheAgreementMember2024-03-310001662579cccc:BiogenAgreementMember2024-03-310001662579cccc:MerckAgreementMember2023-12-310001662579cccc:BettaAgreementMember2023-12-310001662579cccc:RocheAgreementMember2023-12-310001662579cccc:BiogenAgreementMember2023-12-310001662579cccc:RestatedRocheAgreementAndBiogenLicenseAgreementMember2024-03-310001662579srt:MaximumMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMembercccc:AtTheMarketMember2021-11-012021-11-300001662579cccc:EquityDistributionAgreementWithCowenAndCompanyLLCMembercccc:AtTheMarketMember2024-01-012024-03-310001662579cccc:EquityDistributionAgreementWithCowenAndCompanyLLCMembercccc:AtTheMarketMember2024-03-310001662579us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001662579us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001662579us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001662579us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001662579us-gaap:EmployeeStockOptionMember2024-03-310001662579us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001662579cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember2024-03-072024-03-070001662579cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember2024-01-012024-03-310001662579us-gaap:PerformanceSharesMember2024-01-012024-03-310001662579us-gaap:PerformanceSharesMember2024-03-310001662579us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001662579us-gaap:RestrictedStockUnitsRSUMember2024-03-310001662579cccc:OptionsToPurchaseCommonStockMember2024-01-012024-03-310001662579cccc:OptionsToPurchaseCommonStockMember2023-01-012023-03-31

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

________________________________________________

FORM 10-Q

________________________________________________

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number: 001-39567

________________________________________________

C4 Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

________________________________________________


Delaware			47-5617627
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
490 Arsenal Way, Suite 120 Watertown, MA			02472
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (617) 231-0700

________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CCCC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ o No x

As of April 30, 2024, the registrant had 68,805,786 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Form 10-Q, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q may include, but are not limited to, statements about:

•the initiation, timing, progress, results, safety and efficacy, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials, the period during which the results of the trials will become available, and our research and development programs;

•our ability to obtain funding for our operations necessary to complete further development, manufacturing and commercialization of our product candidates;

•our ability to obtain and maintain regulatory approval for any of our current or future product candidates;

•the period of time over which we anticipate our existing cash and cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements;

•our ability to identify and develop product candidates for treatment of additional disease indications;

•the potential attributes and benefits of our product candidates;

•the rate and degree of market acceptance and clinical utility for any product candidates we may develop;

•the pricing and reimbursement of our product candidates, if approved, including the possibility for reduced pricing of our products, once approved, if they are later subject to mandatory price negotiation with the Centers for Medicare and Medicaid Services under the Inflation Reduction Act of 2022 or other applicable laws;

•the effects of competition with respect to any of our current or future product candidates, as well as innovations by current and future competitors in our industry;

•the implementation of our strategic plans for our business, any product candidates we may develop, and our TORPEDO® (Target ORiented ProtEin Degrader Optimizer) platform;

•the ability and willingness of our third-party strategic collaborators to continue research, development, and manufacturing activities relating to our product candidates, including our ability to advance programs under our existing collaboration agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche, Biogen MA, Inc., or Biogen, Betta Pharmaceuticals, Co., Ltd., or Betta Pharma, Merck Sharp & Dohme, LLC, or Merck, and Merck KGaA, Darmstadt, Germany, or MKDG, or other new collaboration agreements;

•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;

•estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;

•future agreements with third parties in connection with the manufacturing and commercialization of our product candidates, if approved;

•the size and growth potential of the markets for our product candidates and our ability to serve those markets;

•our financial performance;

•regulatory developments in the United States and foreign countries;

•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•the success of competing therapies that are or may become available;

•our ability to attract and retain key scientific or management personnel;

•developments relating to our competitors and our industry; and

Table of Contents

•other risks and uncertainties, including those discussed in Part II, Item 1A - Risk Factors in this Form 10-Q.

In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Risk Factors” and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance.

The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.

Table of Contents

SUMMARY OF RISK FACTORS

Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in Part II, Item 1A - Risk Factors in this Form 10-Q. These risks include, among others:

•We are a clinical-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. To date, we have not generated any revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years and may never achieve or maintain profitability. Our net loss was $28.4 million and $34.8 million for the three months ended March 31, 2024 and 2023, respectively.

•We will need substantial additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts.

•Our approach to the discovery and development of product candidates based on our TORPEDO platform is unproven, which makes it difficult to predict the time, cost and likelihood of successfully developing any products.

•While we are a clinical-stage company and have commenced clinical trials of several product candidates, we have never completed a clinical trial of any of our product candidates. Our business could be harmed if we are unable to develop, obtain regulatory approval for and/or commercialize our product candidates, or if we experience significant delays in doing any of these things.

•We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. In addition, the results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of later-stage clinical trials.

•Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent, delay, or require additional research or analysis to proceed with development, regulatory approval, and commercialization of our current and future product candidates.

•We have ongoing collaboration agreements with Roche, Betta Pharma, Merck, and MKDG, as well as a collaboration agreement with Biogen, whose research term expired on June 30, 2023 and research activities were substantially completed as of March 31, 2024. We may also seek to enter into additional collaborations in the future with third parties for the development and/or commercialization of certain of our product candidates. However, we may never realize the full potential benefits under these existing or potential collaboration arrangements.

•We face substantial competition, which may result in others discovering, developing or commercializing products for the same indication and/or patient population before or more successfully than we do.

•We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates in a timely manner, or at an acceptable cost or quality.

•If we are unable to obtain required marketing approvals for, commercialize, manufacture, obtain, and maintain patent protection for or gain market acceptance of our product candidates, or if we experience significant delays in doing so, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.

•If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad or enforceable, our competitors could develop and commercialize technology, product candidates, and products similar or identical to ours, and our ability to successfully commercialize our technology, product candidates, and products may be impaired.

Table of Contents

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “C4 Therapeutics,” “the Company,” “we,” “us,” and “our” in this Form 10-Q refer to C4 Therapeutics, Inc. and its consolidated subsidiary.

NOTE REGARDING TRADEMARKS

We own or have rights to various trademarks, service marks and trade names that are used in connection with the operation of our business, including our company name, C4 Therapeutics, our logo, the name of our TORPEDO technology platform and the names of our BIDAC and MONODAC protein degrader product candidates. This Form 10-Q may also contain trademarks, service marks, and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names, or products in this prospectus is not intended to and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks, and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks, and trade names.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statement of Operations and Comprehensive Loss	2
	Condensed Consolidated Statement of Stockholder’s Equity	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	69
Item 3.	Defaults Upon Senior Securities	69
Item 4.	Mine Safety Disclosures	69
Item 5.	Other Information	69
Item 6.	Exhibits	71
	SIGNATURES	73

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

C4 Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(Unaudited)


	March 31, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	89,659	$	126,590
Marketable securities, current	168,533		127,091
Accounts receivable	13,599		11,799
Prepaid expenses and other current assets	7,801		5,709
Total current assets	279,592		271,189
Marketable securities, non-current	40,975		28,008
Property and equipment, net	6,756		7,132
Right-of-use asset	62,377		63,956
Restricted cash	3,443		3,443
Other assets	5,228		2,723
Total assets	$	398,371	$	376,451
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,630	$	1,446
Accrued expenses and other current liabilities	12,891		20,630
Deferred revenue, current	35,142		15,471
Operating lease liability, current	5,355		5,219
Total current liabilities	55,018		42,766
Deferred revenue, net of current	20,706		21,814
Operating lease liability, net of current	64,365		65,757
Total liabilities	140,089		130,337
Commitments and contingencies (see Note 11)

SEC Form 10-Q filed by C4 Therapeutics Inc.